

PATENT APPLICATION SERIAL NO 08/270631

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

ABSTRACT

[illegible]

20

30

over



TRANSMITTAL OF UTILITY PATENT APPLICATION FOR FILING

Certification under 37 CFR 1.10 (if applicable)

TB 585 979 460 US

"Express Mail" Label Number

July 01, 1994

Date of Deposit

I hereby certify that this Transmittal letter, enclosed application, and any other documents referred to as enclosed herein are being deposited in an envelope with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231

CHARLES K. SHOLTZ

(PRINT NAME OF PERSON MAILING APPLICATION)

(SIGNATURE OF PERSON MAILING APPLICATION)

**NON-INVASIVE LOCALIZATION OF A LIGHT-EMITTING
CONJUGATE IN A MAMMAL**

FIELD OF THE INVENTION

5 The present invention relates to noninvasive methods and compositions for detecting, localizing and tracking light-emitting entities and biological events in a mammalian subject.

10 **REFERENCES**

Blackwell, J.M., et al., *Immunol. Lett.* 30:241-248 (1991).

Bradley, D.J., *Clin. and Exper. Immunol.* 30:130-140 (1977).

15 Brasier, A.R. and Ron, D., *Meth. in Enzymol.* 216:386-396 (1992).

Campbell, A.K., Chemiluminescence. Principles and Applications in Biology and Medicine (Chichester, England: Ellis Horwood Ltd. and VCH Verlagsgesellschaft mbH) (1988).

20 Carter, P.B., and Collins, F.M., *J. Exper. Med.* 139:1189-1203 (1974).

Casadei, J., et al., *PNAS* 87:2047-2051 (1990).

Chalfie, M., et al., *Science* 263:802-805 (1994).

25 Daubner, S.C., et al., *PNAS* 84:8912-8916 (1987).


Dhawan, S., et al., *J. Immunol.* 147(1):102 (1991).

Ducluzeau, R., et al., *Zeut. Bakt.* 5313:533-548

(1970).

RECEIVED TELETYPE

- Fan, N., et al., *J. Clin. Micro.* 30(4):905 (1992).
 Finlay, B.B. and Falkow, S., *Mol. Microbiol.* 3:1833-1841 (1989).
 Forget, A., et al., *Infect. Immunol.* 32:42-47
 5 (1981).
 Frackman, S., et al., *J. Bact.* 172:5767-5773
 (1990).
 Gossen, M. and Bujard, H., *PNAS* 89:5547-5551
 (1992).
 10 Goto, Y., et al., *Immunogenetics* 30:218-221
 (1989).
 Grabau, C., et al., *J Biol Chem.* 266:3294-3299
 (1991).
 Gros, P., et al., *J Immunol.* 127:2417-2421 (1981).
 15 Guzzo, J., et al., *Tox. Lett.* 64/65:687-693
 (1992).
 Harlow, E., et al., *Antibodies: A Laboratory
 Manual*, Chapter 10, pg. 402, Cold Spring Harbor Press
 (1988).
 20 Hoiseth and Stocker, B.A.D. *Nature* 291:238-239
 (1981).
 Hooper, C.E., et al., *J. Biolum. and Chemilum.*
5:123-130 (1990).
 Houston, A.L and Moerner, W.E., U. S. Patent No.
 25 4,614,116, issued 30 September 1986.
 Hsu, H.S., *Microbiol. Rev.* 53:390-409 (1989).
 Israel, S. and Honigman, A., *Gene* 104:139-145
 (1991).
 Jassim, S.A.A., et al., *J. Biolum. Chemilum.*
 30 5:115-122 (1990).
 Korpela, M., et al., *J. Biolum. Chemilum.* 4:551-
 554 (1989).
 Kovacs Sz., F. and Mettenlieter, T.C., *J. Gen.*
Virol. 72:2999-3008 (1991).
 35 Lee, C.A., et al., *PNAS* 87:4304-4308 (1990).



- Maximow, A.A. and Bloom, W., Textbook of Histology, Saunders, Philadelphia (1931).
- McCune, et al., Science 241:1632-1639 (1988)
- Morin, J.G and Hastings, J.W., J. Cell. Physiol. 77:313 (1971).
- O'Kane, D.J., et al., PNAS 88:1100-1104 (1991).
- Plant, J.E. and Glynn, A., J. Infect. Dis. 133:72-78 (1976).
- Pober, J.S. and Cotran, R.S., Lab. Invest. 64:301-305 (1991).
- Popesko, P., et al., A Colour Atlas of Anatomy of Small Laboratory Animals Vol. Two: Rat Mouse Hamster (London England: Wolfe) (1990).
- Prasher, D.C., et al., Biochem. 26:1326-1332
- Sambrook, J., et al., In Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Vol. 2 (1989).
- Skamene, E., et al., Immunogenet. 19:117-120 (1984).
- Skamene, E. and Pietrangeli, C.E., Nature 297:506-509 (1991).
- Stead, W.W., Annals of Intern. Med. 116:937-941 (1992).
- Stead, W.W., et al., New Eng. J. Med. 322:422-427 (1990).
- Szittner, R. and Meighen, E., J. Biol. Chem. 265:16581-16587 (1990).
- Wood, K.V., et al., Science 244:700-702 (1989)
- Xi, L., et al., J. Bact. 173:1399-1405 (1991).

BACKGROUND OF THE INVENTION

The ability to monitor the progression of infectious diseases is limited by the current ex vivo methods of detecting and quantifying infectious agents in tissues. The replication of an infectious agent in

a host often involves primary, secondary and tertiary sites of replication. The sites of replication and the course that an infectious agent follows through these sites is determined by the route of inoculation, factors encoded by the host as well as determinants of the infecting agent.

Experience may offer, in some cases, an estimate of probable sites of replication and the progress of an infection. It is more often the case, however, that the sites of infection, and the pace of the disease are either not known or can only roughly be estimated. Moreover, the progression of an infectious disease, even in inbred strains of mice, is often individualized, and serial, ex vivo analyses of many infected animals need to be conducted to determine, on the average, what course a disease will follow in an experimentally infected host.

Accordingly, it would be desirable to have a means of tracking the progression of infection in an animal model. Ideally, the tracking could be done non-invasively, such that a single animal could be evaluated as often as necessary without detrimental effects. Methods and compositions of the present invention provide a non-invasive approach to detect, localize and track a pathogen, as well as other entities, in a living host, such as a mammal.

SUMMARY OF THE INVENTION

In one embodiment, the invention includes a noninvasive method for detecting the localization of a biocompatible entity in a mammalian subject. The entity can be a molecule, macromolecule, cell, microorganism (including a pathogen), a particle, or the like.

5
10

15

20

25

30

35

imaging and no special immobilization precautions are required. An image from the photon emission data is then constructed.

5 The method described above can be used to track the localization of the entity in the subject over time, by repeating the imaging steps at selected intervals and constructing images corresponding to each of those intervals.

10 The method described above can be used in a number of specific applications, by attaching, conjugating or incorporating targeting moieties onto the entity. The targeting moiety may be an inherent property of the entity (e.g. antibody or antibody fragment), or it may be conjugated to, attached to, or incorporated in the
15 entity (e.g. liposomes containing antibodies). Examples of targeting moieties include antibodies, antibody fragments, enzyme inhibitors, receptor-binding molecules, various toxins and the like. Targets of the targeting moiety may include sites of inflammation,
20 infection, thrombotic plaques and tumor cells. Markers distinguishing these targets, suitable for recognition by targeting moieties, are well known.

Further, the method may be used to detect and localize sites of infection by a pathogen in an animal
25 model, using the pathogen (e.g. Salmonella) conjugated to a light-generating moiety as the entity.

In a related embodiment, the invention includes a noninvasive method for detecting the level of a biocompatible entity in a mammalian subject over time.
30 The method is similar to methods described above, but is designed to detect changes in the level of the entity in the subject over time, without necessarily localizing the entity in the form of an image. This method is particularly useful for monitoring the
35 effects of a therapeutic substance, such as an antibiotic,

447022-1

8

In a related embodiment, the invention includes a noninvasive method for detecting the localization of a promoter-induction event in an animal made transgenic or chimeric for a construct including a gene encoding a light-generating protein under the control of an inducible promoter. Promoter induction events include the administration of a substance which directly activates the promoter, the administration of a substance which stimulates production of an endogenous promoter activator (e.g. stimulation of interferon

production by RNA virus infection), the imposition of conditions resulting in the production of an endogenous promoter activator (e.g. heat shock or stress), and the like. The event is triggered, and the animal is imaged as described above.

In yet another embodiment, the invention includes pathogens, such as Salmonella, transformed with a gene expressing a light-generating protein, such as luciferase.

In another aspect, the invention includes a method of identifying therapeutic compounds effective to inhibit spread of infection by a pathogen. The method includes administering a conjugate of the pathogen and a light-generating moiety to control and experimental animals, treating the experimental animals with a putative therapeutic compound, localizing the light-emitting pathogen in both control and experimental animals by the methods described above, and identifying the compound as therapeutic if the compound is effective to significantly inhibit the spread or replication of the pathogen in the experimental animals relative to control animals. The conjugates include a fluorescently-labeled antibodies, fluorescently-labeled particles, fluorescently-labeled small molecules, and the like.

In still another aspect, the invention includes a method of localizing entities conjugated to light-generating moieties through media of varying opacity. The method includes the use of photodetector device to detect photons transmitted through the medium, integrate the photons over time, and generate an image based on the integrated signal.

In yet another embodiment, the invention includes a method of measuring the concentration of selected substances, such as dissolved oxygen or calcium, at

08270631 000000

15

30

5

10

15

20

25

30

integrating over 30 seconds. Air pockets are present in each tube on both sides of the suspension.

Figure 4 is a schematic diagram of a vial used to test the transmission of light generated by LB5000lux through animal tissue.

Figures 5A-F show composite images of Balb/c mice orally inoculated with low virulence LB5000lux (Figs. 5A-B), non-invasive BJ66lux (Figs. 5C-D) and virulent SL1344lux (Figs. 5E-F) salmonella, and imaged at the times indicated in the figure. The luminescence signal was integrated over 5 minutes.

Figure 6 is a composite image showing the distribution of salmonella in mice 32 hours following intraperitoneal (i.p.) injections with either virulent SL1344lux (left two animals) or low virulence LB5000lux (right two animals) strains of the bacterium.

Figures 7A and 7B show the distribution of virulent salmonella in mice resistant to systemic salmonella infections (129 x Balb/c, *Ity^{r/s}*). Figure 7A - day 1, Figure 7B - day 8.

Figures 8A-C show the distribution of mutant salmonella with reduced virulence (BJ66lux) seven days following oral inoculation. Figure 8A shows external, non-invasive imaging of the luminescence. Figure 8B shows the same animal imaged following laparotomy. Labeled organs are C - cecum, L - liver, I - small intestine and Sp - spleen. Figure 8C shows a post-laparotomy image generated following injection of air into the lumen of the intestine both anterior and posterior to the cecum.

Figures 9A, 9B and 9C show the distribution of salmonella SL1344lux in susceptible Balb/c mice following intraperitoneal inoculation with SL1344lux. Figure 9A was imaged prior to the opening of the

467040-TE902280

Figures 10A-E show the effects of ciprofloxacin treatment on bioluminescence from SL1344lux salmonella in orally-inoculated mice. Figure 10A shows a graph of the relative bioluminescence intensity, measured from the abdominal area, as a function of time after initiation of treatment, for treated and untreated animals. Figures 10B and 10D show composite images of mice 8 days after oral inoculation with SL1344lux salmonella, before treatment with ciprofloxacin. Figures 10C and 10E show composite images of the same mice 5.5 hours either following treatment (Fig. 10E) or control (no treatment; Fig. 10C).

I. Definitions

25 Opaque medium is used herein to refer to a medium that is "traditionally" opaque, not necessarily absolutely opaque. Accordingly, an opaque medium is defined as a medium that is commonly considered to be neither transparent nor translucent, and includes items such as a wood board, and flesh and skin of a mammal.

Biocompatible entity is an entity that can be administered to a mammal. This includes pathogens which may be deleterious to the mammal. In reference

5 Light-generating is defined as capable of
generating light through a chemical reaction or through
the absorption of radiation.

Spread of infection typically refers to the spreading and colonization by a pathogen of host sites other than the initial infection site. The term can also include, however, growth in size and/or number of the pathogen at the initial infection site.

luc - eukaryotic genes associated with luciferase and photon emission.

Heterologous gene refers to a gene which has been transfected into a host organism. Typically, a
25 heterologous gene refers to a gene that is not originally derived from the transfected or transformed cells' genomic DNA.

30 The present invention includes methods and
compositions relating to non-invasive imaging and/or
detecting of light-emitting conjugates in mammalian
subjects. The conjugates contain a biocompatible
entity and a light-generating moiety. Biocompatible
35 entities include, but are not limited to, small

09270634-030144

Page 14 of APPLICATION

MISSING from the file

5

10

15

20

20

25

30

5

10

20

30

the red range) more readily than it does shorter wavelength light.

Accordingly, LGMs which emit light in the range of yellow to red (550 - 1100 nm) are typically preferable to LGMs which emit at shorter wavelengths. Several of the LGMs discussed below emit in this range. However, it will be noted, based on experiments performed in support of the present invention and presented below, that excellent results can be achieved in practicing the present invention with LGMs that emit in the range of 486 nm, despite the fact that this is not an optimal emission wavelength. These results are possible, in part, due to the relatively high concentration of LGMs (luciferase molecules) present in the LECs (transformed Salmonella cells) used in these experiments, and to the use of a sensitive detector. It will be understood that through the use of LGMs with a more optimal emission wavelength, similar detection results can be obtained with LGEs having lower concentrations of the LGMs.

2. Fluorescence-based Moieties. Fluorescence is the luminescence of a substance from a single electronically excited state, which is of very short duration after removal of the source of radiation. The wavelength of the emitted fluorescence light is longer than that of the exciting illumination (Stokes' Law), because part of the exciting light is converted into heat by the fluorescent molecule.

Because fluorescent molecules require input of light in order to luminesce, their use in the present invention may be more complicated than the use of bioluminescent molecules. Precautions are typically taken to shield the excitatory light so as not to contaminate the fluorescence photon signal being

1677064-0704

5
10

15
20

25

30

35

10

25

30

35

5 moieties, is that there is virtually no background in the signal. The only light detected is light that is produced by the exogenous bioluminescent moiety. In contrast, the light used to excite a fluorescent molecule often results in the fluorescence of
10 substances other than the intended target. This is particularly true when the "background" is as complex as the internal environment of a living animal.

15 et al.) and the aequorin family (e.g. Prasher, et al.).
Members of the luciferase family have been identified
in a variety of prokaryotic and eukaryotic organisms.
Luciferase and other enzymes involved in the
prokaryotic luminescent (*lux*) systems, as well as the
20 corresponding *lux* genes, have been isolated from marine
bacteria in the *Vibrio* and *Photobacterium* genera and
from terrestrial bacteria in the *Xenorhabdus* genus.

25 *Photinus pyralis*. Firefly luciferase has been
extensively studied, and is widely used in ATP assays.
cDNAs encoding luciferases from *Pyrophorus*
plagiophthalmus, another species of click beetle, have
been cloned and expressed (Wood, et al.). This beetle
30 is unusual in that different members of the species
emit bioluminescence of different colors. Four classes
of clones, having 95-99% homology with each other, were
isolated. They emit light at 546 nm (green), 560 nm
(yellow-green), 578 nm (yellow) and 593 nm (orange).
35 The last class (593 nm) may be particularly

advantageous for use as a light-generating moiety with the present invention, because the emitted light has a wavelength that penetrates tissues more easily than shorter wavelength light.

5 Luciferases, as well as aequorin-like molecules, require a source of energy, such as ATP, NAD(P)H, and the like, and a substrate, such as luciferin or coelentrizine and oxygen.

10 The substrate luciferin must be supplied to the luciferase enzyme in order for it to luminesce. In those cases where a luciferase enzyme is introduced as an expression product of a vector containing cDNA encoding a *lux* luciferase, a convenient method for providing luciferin is to express not only the
15 luciferase but also the biosynthetic enzymes for the synthesis of luciferin. In cells transformed with such a construct, oxygen is the only extrinsic requirement for bioluminescence. Such an approach, detailed in Example 1, is employed to generate *lux*-transformed
20 *Salmonella*, which are used in experiments performed in support of the present invention and detailed herein.

25 The plasmid construct, encoding the *lux* operon obtained from the soil bacterium *Xenorhabdus luminescens* (Frackman, et al., 1990), confers on transformed *E. coli* the ability to emit photons through the expression of the two subunits of the heterodimeric luciferase and three accessory proteins (Frackman, et al., 1990). Optimal bioluminescence for *E. coli* expressing the *lux* genes of *X. luminescens* is observed
30 at 37°C (Szittner, et al., Xi, et al.) in contrast to the low temperature optima of luciferases from eukaryotic and other prokaryotic luminescent organisms (Campbell, 1988). The luciferase from *X. luminescens*, therefore, is well-suited for use as a marker for
35 studies in animals.

08270634 070494

22

Luciferase vector constructs such as the one described above and in Example 1, can be adapted for use in transforming a variety of host cells, including most bacteria, and many eukaryotic cells (*luc* constructs). In addition, certain viruses, such as herpes virus and vaccinia virus, can be genetically-engineered to express luciferase. For example, Kovacs, et al. teach the stable expression of the gene encoding firefly luciferase in a herpes virus. Brasier, et al., teach the use of luciferase gene constructs in mammalian cells. Luciferase expression from mammalian cells in culture has been studied using CCD imaging both macroscopically (Israel and Honigman, 1991) and microscopically (Hooper, et al., 1990).

15

B. Entities

The invention includes entities which have been modified or conjugated to include a light-generating moiety, construct or molecule, such as described above. Such conjugated or modified entities are referred to as light-emitting entities, light-emitting conjugates (LECs) or simply conjugates. The entities themselves may take the form of, for example, molecules, macromolecules, particles, microorganisms, or cells. The methods used to conjugate a light-generating moiety to an entity depend on the nature of the moiety and the entity. Exemplary conjugation methods are discussed in the context of the entities described below.

1. Small molecules. Small molecule entities which may be useful in the practice of the present invention include compounds which specifically interact with a pathogen or an endogenous ligand or receptor. Examples of such molecules include, but are not limited to, drugs or therapeutic compounds; toxins,

such as those present in the venoms of poisonous organisms, including certain species of spiders, snakes, scorpions, dinoflagellates, marine snails and bacteria; growth factors, such as NGF, PDGF, TGF and
5 TNF; cytokines; and bioactive peptides.

The small molecules are preferably conjugated to light-generating moieties that interfere only minimally, if at all, with the bioactivity of the small molecule, such as small fluorescent molecules
10 (described above). Conjugations are typically chemical in nature, and can be performed by any of a variety of methods known to those skilled in the art.

The small molecule entity may be synthesized to contain a light-generating moiety, so that no formal
15 conjugation procedure is necessary. Alternatively, the small molecule entity may be synthesized with a reactive group that can react with the light generating moiety, or *vice versa*.

Small molecules conjugated to light-generating
20 moieties of the present invention may be used either in animal models of human conditions or diseases, or directly in human subjects to be treated. For example, a small molecule which binds with high affinity to receptor expressed on tumor cells may be used in an
25 animal model to localize and obtain size estimates of tumors, and to monitor changes in tumor growth or metastasis following treatment with a putative therapeutic agent. Such molecules may also be used to monitor tumor characteristics, as described above, in
30 cancer patients.

2. Macromolecules. Macromolecules, such as polymers and biopolymers, constitute another example of entities useful in practicing the present invention.
35 Exemplary macromolecules include antibodies, antibody

407047 1290230

fragments, fusion proteins and certain vector constructs.

Antibodies or antibody fragments, purchased from commercial sources or made by methods known in the art (Harlow), can be used to localize their antigen in a mammalian subject by conjugating the antibodies to a light-generating moiety, administering the conjugate to a subject by, for example, injection, allowing the conjugate to localize to the site of the antigen, and imaging the conjugate.

Antibodies and antibody fragments have several advantages for use as entities in the present invention. By their nature, they constitute their own targeting moieties. Further, their size makes them amenable to conjugation with several types of light-generating moieties, including small fluorescent molecules and fluorescent and bioluminescent proteins, yet allows them to diffuse rapidly relative to, for example, cells or liposomes.

The light-generating moieties can be conjugated directly to the antibodies or fragments, or indirectly by using, for example, a fluorescent secondary antibody. Direct conjugation can be accomplished by standard chemical coupling of, for example, a fluorophore to the antibody or antibody fragment, or through genetic engineering. Chimeras, or fusion proteins can be constructed which contain an antibody or antibody fragment coupled to a fluorescent or bioluminescent protein. For example, Casadei, et al., describe a method of making a vector construct capable of expressing a fusion protein of aequorin and an antibody gene in mammalian cells.

Conjugates containing antibodies can be used in a number of applications of the present invention. For example, a labeled antibody directed against E-

467027-1E30Z30

25

selection, which is expressed at sites of inflammation, can be used to localize the inflammation and to monitor the effects of putative anti-inflammatory agents.

Vector constructs by themselves can also
5 constitute macromolecular entities applicable to the present invention. For example, a eukaryotic expression vector can be constructed which contains a therapeutic gene and a gene encoding a light-generating molecule under the control of a selected promoter (i.e.
10 a promoter which is expressed in the cells targeted by the therapeutic gene). Expression of the light-generating molecule, assayed using methods of the present invention, can be used to determine the location and level of expression of the therapeutic
15 gene. This approach may be particularly useful in cases where the expression of the therapeutic gene has no immediate phenotype in the treated individual or animal model.

20 3. Viruses. Another entity useful for certain aspects of the invention are viruses. As many viruses are pathogens which infect mammalian hosts, the viruses may be conjugated to a light-generating moiety and used to study the initial site and spread of
25 infection. In addition, viruses labeled with a light-generating moiety may be used to screen for drugs which inhibit the infection or the spread of infection.

A virus may be labeled indirectly, either with an antibody conjugated to a light-generating moiety, or
30 by, for example, biotinylating virions (e.g. by the method of Dhawan, et al.) and then exposing them to streptavidin linked to a detectable moiety, such as a fluorescent molecule.

Alternatively, virions may be labeled directly
35 with a fluorophore like rhodamine, using, for example,

467007E90/280

5

10

20

35

liposome may carry luciferase, while the other carries luciferin. The liposomes may carry targeting moieties, and the targeting moieties on the two liposomes may be the same or different. Viral proteins on infected
 5 cells can be used to identify infected tissues or organs. Cells of the immune system can be localized using a single or multiple cell surface markers.

The liposomes are preferably surface-coated, e.g., by incorporation of phospholipid - polyethyleneglycol
 10 conjugates, to extend blood circulation time and allow for greater targeting via the bloodstream. Liposomes of this type are well known.

5. Cells. Cells, both prokaryotic and
 15 eukaryotic, constitute another entity useful in the practice of the present invention. Like particles, cells can be loaded with relatively high concentrations of light-generating moieties, but have the advantage that the light-generating moieties can be provided by,
 20 for example, a heterologous genetic construct used to transfect the cells. In addition, cells can be selected that express "targeting moieties", or molecules effective to target them to desired locations within the subject. Alternatively, the cells can be
 25 transfected with a vector construct expressing an appropriate targeting moiety.

The cell type used depends on the application. For example, as is detailed below, bacterial cells, such as salmonella, can be used to study the infective
 30 process, and to evaluate the effects of drugs or therapeutic agents on the infective process with a high level of temporal and spatial resolution.

Bacterial cells constitute effective entities. For example, they can be easily transfected to express
 35 a high levels of a light-generating moiety, as well as

08270631-070194

Pathogenic bacteria can be conjugated to a light-generating moiety and used in an animal model to follow the infection process *in vivo* and to evaluate potential anti-infective drugs, such as new antibiotics, for their efficacy in inhibiting the infection. An example of this application is illustrated by experiments performed in support of the present invention and detailed below.

30 Expression of the light-generating protein in transformed cells can be regulated using any of a variety of selected promoters. For example, if the cells are to be used as light-emitting entities targeted to a site in the subject by an expressed
35 ligand or receptor, a constitutively-active promoter,

Alternatively, the transformed cells may be administered such they become uniformly distributed in the subject, and express the light-generating protein only under certain conditions, such as upon infection by a virus or stimulation by a cytokine. Promoters that respond to factors associated with these and other stimuli are known in the art. In a related aspect, inducible promoters, such as the Tet system (Gossen, et al.) can be used to transiently activate expression of the light-generating protein.

Tumor cell lines transformed as above, for example, with a constitutively-active promoter, may be used to monitor the growth and metastasis of tumors.

25 Transformed tumor cells may be injected into an animal model, allowed to form a tumor mass, and the size and metastasis of the tumor mass monitored during treatment with putative growth or metastasis inhibitors.

6. Cell Transformation. Transformation
35 methods for both prokaryotic cells and eukaryotic cells

IV. Transgenic Animals Containing Genes Encoding Light-Generating Proteins

Activation of the promoter results in increased expression of the genes encoding the light-generating molecules and accessory proteins. Activation of the promoter is achieved by the interaction of a selected biocompatible entity, or parts of the entity, with the promoter elements. If the activation occurs only in a part of the animal, only cells in that part will express the light-generating protein.

In a related aspect, a promoter expressed in certain disease states can be used to mark affected areas in a transgenic animal, and expression of the light-generating moiety can be used to monitor the effects of treatments for the disease state. For example, E-selection is expressed at sites of :

31

E-selection promoter can be isolated and used to drive the expression of a luciferase gene.

It is also possible to use methods of the invention with tissue-specific promoters. This enables, for example, the screening of compounds which are effective to inhibit pathogenic processes resulting in the degeneration of a particular organ or tissue in the body, and permits the tracking of cells (e.g. neurons) in, for example, a developing animal.

Many promoters which are applicable for use with the present invention are known in the art. In addition, methods are known for isolating promoters of cloned genes, using information from the gene's cDNA to isolate promoter-containing genomic DNA.

V. Imaging of Light-Emitting Conjugates

Light emitting conjugates that have localized to their intended sites in a subject may be imaged in a number of ways. Guidelines for such imaging, as well as specific examples, are described below.

A. Localization of Light-Emitting Conjugates

In the case of "targeted" entities, that is, entities which contain a targeting moiety - a molecule or feature designed to localize the entity within a subject or animal at a particular site or sites, localization refers to a state when an equilibrium between bound, "localized", and unbound, "free" entities within a subject has been essentially achieved. The rate at which such an equilibrium is achieved depends upon the route of administration. For example, a conjugate administered by intravenous injection to localize thrombi may achieve localization, or accumulation at the thrombi, within minutes of injection. On the other hand, a conjugate administered

06270631 070194
15 20 25 30 35

Alternatively, localization may simply refer to the location of the entity within the subject or animal at selected time periods after the entity is administered. For example, in experiments detailed herein, Salmonella are administered (e.g., orally) and their spread is followed as a function of time. In this case, the entity can be "localized" immediately following the oral introduction, inasmuch as it marks the initial location of the administered bacteria, and its subsequent spread or recession (also "localization") may be followed by imaging.

By way of another example, localization is achieved when an entity becomes distributed following administration. For example, in the case of a conjugate administered to measure the oxygen concentration in various organs throughout the subject or animal, the conjugate becomes "localized", or informative, when it has achieved an essentially steady-state of distribution in the subject or animal.

B. Photodetector Devices

3b

5 In cases where it is possible to use light-
generating moieties which are extremely bright, and/or
to detect light-emitting conjugates localized near the
surface of the subject or animal being imaged, a pair
of "night-vision" goggles or a standard high-
0 sensitivity video camera, such as a Silicon Intensified
Tube (SIT) camera (e.g. Hamamatsu Photonic Systems,
Bridgewater, NJ), may be used. More typically,
however, a more sensitive method of light detection is
required.

By accumulating these detected photons in a digital image processor over time, an image can be acquired and constructed. In contrast to conventional cameras where the signal at each image point is assigned an intensity value, in photon counting imaging the amplitude of the signal carries no significance. The objective is to simply detect the presence of a signal (photon) and to count the occurrence of the signal with respect to its position over time.

34

Even greater sensitivity can be achieved by placing intensifying microchannel arrays in series, so that electrons generated in the first stage in turn result in an amplified signal of electrons at the second stage. Increases in sensitivity, however, are achieved at the expense of spatial resolution, which decreases with each additional stage of amplification.

3. Image Processors. Signals generated by
15 photodetector devices which count photons need to be
processed by an image processor in order to construct
an image which can be, for example, displayed on a
monitor or printed on a video printer. Such image
20 processors are typically sold as part of systems which
include the sensitive photon-counting cameras described
above, and accordingly, are available from the same
sources (e.g. Photometrics, Ltd., and Hamamatsu).
Image processors from other vendors can also be used,
but more effort is generally required to achieve a
25 functional system.

35

51

5

10

15

25

30

35

5

10

15

20

30

of the subject, need to be considered to preserve the spatial information in the constructed image. For example, in a case where the subject is a person and photon emission measurement time is on the order of a few seconds, the subject may simply be asked to remain as still as possible during photon emission measurement (imaging). On the other hand, if the subject is an animal, such as a mouse, the subject can be immobilized using, for example, an anesthetic or a mechanical restraining device.

A variety of restraining devices may be constructed. For example, a restraining device effective to immobilize a mouse for tens of seconds to minutes may be built by fastening a plexiglass sheet over a foam cushion. The cushion has an indentation for the animal's head at one end. The animal is placed under the plexiglass such that its head is over the indentation, allowing it to breathe freely, yet the movement of its body is constrained by the foam cushion.

In cases where it is desired to measure only the total amount of light emanating from a subject or animal, the subject does not necessarily need to be immobilized, even for long periods of photon emission measurements. All that is required is that the subject be confined to the detection field of the photodetector during imaging. It will be appreciated, however, that immobilizing the subject during such measuring may improve the consistency of results obtained, because the thickness of tissue through which detected photons pass will be more uniform from animal to animal.

08270631 070494

D. Further Considerations During Imaging

1. Fluorescent Light-Generating Moieties.

The visualization of fluorescent light-generating moieties requires an excitation light source, as well
 5 as a photodetector. Furthermore, it will be understood that the excitation light source is turned on during the measuring of photon emission from the light-generating moiety.

Appropriate selection of a fluorophore, placement
 10 of the light source and selection and placement of filters, all of which facilitate the construction of an informative image, are discussed above, in the section on fluorescent light-generating moieties.

15 2. High-Resolution Imaging. Photon scattering by tissue limits the resolution that can be obtained by imaging LGMs through a measurement of total photon emission. It will be understood that the present invention also includes embodiments in which
 20 the light-generation of LGMs is synchronized to an external source which can be focused at selected points within the subject, but which does not scatter significantly in tissue, allowing the construction of higher-resolution images. For example, a focused
 25 ultrasound signal can be used to scan, in three dimensions, the subject being imaged. Light-generation from areas which are in the focal point of the ultrasound can be resolved from other photon emission by a characteristic oscillation imparted to the light
 30 by the ultrasound (e.g. Houston, et al.)

E. Constructing an Image of Photon Emission

In cases where, due to an exceptionally bright light-generating moiety and/or localization of light-
 35 emitting conjugates near the surface of the subject, a

167022740230

5

10

30

The image of photon emission is typically superimposed on the greyscale image to produce a composite image of photon emission in relation to the subject.

15

20

25

30

35

12

human typhoid. A mouse virulent *Salmonella typhimurium* strain, SL1344 (Hoiseth and Stocker, 1981), a non-invasive mutant of SL1344, BJ66 and a low virulence LT-2 strain of salmonella, LB5000 were each marked with a plasmid containing the *lux* operon, and used in experiments to localize salmonella infection in mice.

A. Constructions of Luminescent Salmonella

1. Salmonella Strains. Three strains of *Salmonella typhimurium* with differing virulence phenotypes, defined by oral and intra-peritoneal inoculations into mice, are selected for transformation.

The most virulent phenotype used herein is SL1344, a mouse strain originally obtained from a fatal infection of a calf (Hoiseth and Stocker 1981). Following oral inoculations of mice with this strain, bacteria are disseminated systematically via the lymphatic system resulting in colonization of the liver, spleen and bone marrow (Carter and Collins, 1974; see also reviews by Finlay, et al., 1989, and Hsu, 1989).

A non-invasive mutant of SL1344, BJ66, is also evaluated. Systemic infections in mice do not typically result from an oral inoculation with BJ66, but do result from intraperitoneal inoculations with this strain.

A low virulence LT-2 strain of salmonella, LB5000, is also examined. LT-2 stains are laboratory strains known to be of reduced or variable virulence for mice. LB5000 contains multiple auxotrophic mutations, is streptomycin resistant, and is cleared from mice following oral or intraperitoneal inoculations.

115700-01202200

with the lux Operon. The three strains are each transformed with a plasmid encoding the lux operon, as detailed in Example 1. The plasmid, obtained from the soil bacterium *Xenorhabdus luminescens* (Frackman, et al., 1990) confers on *E coli* the ability to emit photons through the expression of the two subunits of the heterodimeric luciferase and three accessory proteins, luxC, luxD and luxE.

10 Inclusion of luxC, luxD and luxE removes the
necessity of providing the fatty aldehyde substrate,
luciferin, to the luciferase-expressing cells. Because
supplying the substrate to eukaryotic luciferase
enzymes in an *in vivo* system such as described herein
15 may prove difficult, the entire *lux* operon of *X.*
luminescens is used. The operon also encodes the
enzymes for the biosynthesis of the fatty aldehyde
substrate.

X. *luminescens* luciferase, an alpha-beta heterodimeric mixed-function oxidase, catalyzes the oxidation of reduced flavin and long-chain aldehyde to oxidized flavin and the corresponding long-chain fatty acid. A fatty acid reductase complex is required for the generation and recycling of fatty acid to aldehyde, and an NAD(P)H:flavin oxidoreductase supplies the reduced flavin.

Optimal bioluminescence for *E. Coli* expressing the *lux* genes of *X. luminescens* is 37°C (Szittner and Meighen, Xi, et al.). In contrast, luciferases from eukaryotic and other prokaryotic luminescent organisms typically have lower temperature optima (Campbell). The luciferase from *X. luminescens*, therefore, is well-suited for use as a marker for studies in animals.

244

the entire *X. luminescens lux* operon and confers resistance to ampicillin and carbenicillin on the salmonella (Frackman, et al., 1990). The *X. luminescens lux* operon contains the genes *luxA*, *luxB*, *luxC*, *luxD* and *luxE* (Frackman, et al., 1990). *LuxA* and *B* encode the two subunits of the heterodimeric luciferase. *luxC* and *D* encode the biosynthetic enzymes for the luciferase substrate and *luxE* is a regulatory gene. Inclusion of the genes for the biosynthesis of the substrate is a convenient means of providing substrate to luciferase, in contrast to supplying luciferin externally to the cells in culture or treating animals with the substrate.

15 B. Characterization of Transformed Salmonella In Vitro

1. Adherence and Invasive Properties. The adherence and invasive properties of the three salmonella strains containing the *lux* plasmid are compared in culture, to each other, and to their non-luminescent parental strains by the standard invasion assay as described by Finlay, et al., and detailed in Example 2.

In this assay, adherent and intracellular bacteria are quantified following incubation with an epithelial cell line and peritoneal macrophages. The adherent and intracellular bacteria are detected and quantified by both the emission of photons from living cells, and colony forming units following lysis and plating the cell lysates on carbenicillin-containing plates.

The results of some of the assays are shown in Figures 2A through 2E and discussed in Example 8. The phenotypes of the three strains transformed with the *lux* expressing plasmid are not significantly altered in comparison to the parental salmonella strains. In

5

10

15

20

25

30

5

10

15

20

25

30

persists and remains localized at a single site (Fig. 5D).

b. I.P. Inoculation. To assess whether or
5 not there is sufficient O_2 at the sites of salmonella
replication for the oxidation of luciferin and
subsequent luminescence (Campbell), photon emission is
measured from the tissues of a respiring animal.
Luminescent SL1344lux and LB5000lux are inoculated into
10 the peritoneal cavities of two groups of Balb/c mice.
32 hours post inoculation (p.i.), the transmitted
photons are imaged (Figure 6).

In the mice infected with SL1344lux (left part of
figure), transmitted photons are evident over a large
15 surface, with foci of varying intensities visible.
These images are indicative of a disseminated
infection, and are consistent with widespread
colonization of the viscera, possibly including the
liver and mesenteric lymph nodes. In contrast, the
20 distributions of transmitted photons from animals
infected with the LB5000lux strain is very limited,
indicating a limited infection.

The LB5000lux-infected mice remained healthy for
several weeks p.i., while the SL1344lux-infected mice
25 were nearly moribund and euthanized at 4 days p.i.

These experiments indicate that the level of O_2 in
the blood and or tissues is adequate for
bioluminescence of lux luciferase expressed by
salmonella. Furthermore, the experiments are
30 consistent with the invasive nature of the virulent
strain SL1344 in comparison to the reduced virulent
laboratory strain LB5000.

44703-TE902200

c. Infection of Resistant Mice. Mice which are heterozygous at the *Ity* locus (*Ity^{r/s}*) are resistant to systemic infections by *S. typhimurium* (Plant and Glynn, 1976). This locus, also called *Bcg* (Gros, et al., 1981) or *Lsh* (Bradley, 1977), regulates the pathogenic processes of certain intracellular pathogens, such as *Mycobacterium lepraemurium* (Forget, et al.), *M. Bovis* (Skamene, et al.) and *M. intracellulare* (Goto, et al.). An analogous genetic control of resistance and susceptibility to intracellular pathogens appears to be in humans as well (*M. tuberculosis* (Stead, Stead, et al.) and *M. leprae*).

The *Ity* locus is located on mouse chromosome 1 with two allelic forms, *Ity^r* (resistant, dominant) and *Ity^s* (sensitive, recessive). The gene encoded at the *Ity* locus apparently affects the ability of macrophages to disrupt the internalized pathogens (reviewed by Blackwell, et al.; see also Skamene, et al.) which in turn, affects the down stream function of the proposed macrophage-mediated transport of pathogens to other sites within the infected host. Balb/c mice are *Ity^{s/s}* and 129 mice are *Ity^{r/r}*. The heterozygous Balb/c x 129 mice (*Ity^{r/s}*) are used in experiments detailed herein.

Resistant 129xBalb/c (*Ity^{r/s}*) viable mice are infected by intragastric inoculation of 1×10^7 SL1344lux salmonella as detailed in Example 7. The animals are imaged daily for 8 days post injection (d.p.i.).

Results are shown in Figures 7A (day 1) and 7B (day 8). The luminescence, detected by external imaging, is apparent at 24 h p.i., and appeared to be localized to a single site in all animals. The luminescent signal is present throughout the study

period (up to 8 days p.i.). The intensity of the luminescence and the location of the luminescent source is somewhat variable over time within a mouse and also from mouse to mouse. The luminescent tissue in all
 5 infected animals is the cecum (see below) and the variability in localization, and possibly intensity, is most likely due fact that internal organs of rodents are not tightly fixed in position.

The apparent limited infection observed in these
 10 animals supports the interpretation that the *Ity* restriction blocks macrophage transport. The persistence of this infection for 10 days, however, suggests that there is adherence to the intestine mucosa and prolonged shedding of bacteria in the feces
 15 of these animals, as evidenced by luminescent fecal pellets. These results indicate that the luminescent phenotype of the salmonella in vivo is retained over an 8 day duration in *Ity* restricted animals and that localization is possible following an oral inoculation.

20

d. Internal Imaging Following Oral Inoculation. In order to further localize the luminescent signal in the abdominal cavity, infected mice are imaged following laparotomy (Example 8). The
 25 predominant disease manifestation in all of the animals infected by the oral route is an enlarged cecum (Figs. 8A-C). The "external" image (Fig. 8A) illustrates a focal luminescence, which is revealed in the post-laparotomy image (Fig. 8B) to be the cecum.

30 Injection of air into the intestine confirms the presence of bacteria in other regions of the digestive tract. Bacteria in the colon and rectum are likely expressing luciferase, but low oxygen concentrations are likely limiting light emission from these sites.

9827031 0744
 441040 1230280

The images obtained from oral inoculation studies indicate that the luminescent signal, at 2 days p.i. and at 7 days p.i., localizes almost entirely to the cecum in each of the animals (Popesko, et al.) except those infected with LB5000lux. Luminescence is also apparent in the colon in some animals. By 7 days p.i., no luminescence is detectable in the LB5000lux-infected animals. The CFU present in the organs of these mice are determined at 2 and 5 d p.i.

In animals infected intragastrically with the invasive strain, SL1344lux, the luminescence in the cecum appears early and precedes a systemic infection. In contrast, infections with the non-invasive BJ66lux strain result in a persistent luminescence from the cecum that remains, in some animals, for the entire course of the study (8 days). By 8 days p.i., luminescence is detected over much of the abdominal surface, resembling the distribution of photons following an i.p. inoculation, in the SL1344lux infected mice.

Infections with SL1344lux appear to become systemic, as predicted, with progressively more photons being emitted from an increasing surface area. Luminescence appears to localize over the abdomen in infections with all strains with little detectable luminescence from outside this area. A large number of transmitted photons are localized as a single focus over the abdomen suggesting that even though the infection may be systemic, the greatest amount of replication may be in areas surrounding the intestine.

Localization of the luminescence over the cecum indicates that not only are there large numbers of organisms in this region of the intestine, but also suggests that the Salmonella associate with cells of the mucosa such that they can obtain sufficient oxygen

467042 FEB 22 1964

5 luciferase reaction is not expected to be functional in
the intestine unless the bacteria can obtain oxygen
from cells of the intestinal epithelium.

Monitoring the progression of infections to
15 different tissues may greatly enhance the ability to
understand these steps in the pathogenic process, and
enable the screening for compounds effective to inhibit
the pathogen at selected steps.

52

f. Effects of Ciprofloxacin on Salmonella Infection. Experiments, detailed in Example 10, are performed to demonstrate that non-invasive imaging is useful for following the response of an infection to drugs. Mice are orally inoculated with SL1344lux and treated with 100 mg of ciprofloxacin, an antibiotic effective against salmonella infections. The mice are imaged at selected time periods following treatment, and the extent of infection is quantitated by measuring photon emission. Photon emission in treated mice is compared to values before the initiation of treatment, and to values from control mice that had been infected, but not treated. Results from one such experiment are shown in Figures 10A-E and discussed in Example 10. Infection is significantly reduced in mice treated with the antibiotic, compared both to the levels of pathogen at time zero in treated animals, and to levels of pathogen in control animals throughout the treatment period.

g. Effects of Carbenicillin Selection. Ducluzeau, et al., demonstrated that treatment of animals with antibiotics facilitated colonization of the cecum with Salmonella. The mice in the present experiments are maintained on an antibiotic regime of intramuscular injections of carbenicillin for the purpose of selecting the Amp^r Salmonella containing the luciferase clone. This treatment may alter the course of the gastrointestinal infection, but the observation that Salmonella can associate with the cells lining the cecum indicates that oxygen is available for luminescence. This observation is notable, since the lumen of the cecum is commonly thought to be an anaerobic environment.

RECEIVED
FEB 27 1994

VIII. Applications

A. Determination of Oxygen Levels

The oxygen requirement for luminescence of luciferase evidenced in the experiments summarized above indicates that the present invention may be applicable as a method of determining spatial gradients of oxygen concentration in a subject. Luminescent bacteria have been used to measure oxygen levels in the range of 10 - 1 mM. The studies predict that 0.1 nM is the lower limit of detection (Campbell). The imaging methods described herein may be used for studying oxygen levels at various sites in living animals. For example, microorganisms that have been engineered to emit light in an O₂ or Ca²⁺ -dependent manner could be used as biosensors in a subject, much like luminescent bacteria are used in environmental analyses (Guzzo, et al., Korpela, et al., Jassim, et al.). The dynamic range of luminescence with respect to O₂ concentration is much broader and reaches lower O₂ concentrations than O₂ probes (Campbell). Moreover, light emission in proportion to O₂ concentration is linear over a range of 30 nM to 8 mM, and 9 mM O₂ is required for 1/2 maximal luminescence.

B. Localization of Tumor Cells

The growth and metastatic spread of tumors in a subject may be monitored using methods and compositions of the present invention. In particular, in cases where an individual is diagnosed with a primary tumor, LECs directed against the cells of the tumor can be used to both define the boundaries of the tumor, and to determine whether cells from the primary tumor mass have migrated and colonized distal sites.

For example, LECs, such as liposomes containing antibodies directed against tumor antigens and loaded with LGMs, can be administered to a subject, allowed to bind to tumor cells in the subject, imaged, and the areas of photon emission can be correlated with areas of tumor cells.

In a related aspect, images utilizing tumor-localizing LECs, such as those described above, may be generated at selected time intervals to monitor tumor growth, progression and metastasis in a subject over time. Such monitoring may be useful to record results of anti-tumor therapy, or as part of a screen of putative therapeutic compounds useful in inhibiting tumor growth or metastasis.

Alternatively, tumor cells can be transformed with a luciferase construct under the control of a constitutively-active promoter, and used to induce luminescent tumors in animal models, as described above. Such animal models can be used for evaluating the effects of putative anti-tumor compounds.

C. Localization of Inflammation

In an analogous manner to that described above, compositions and methods of the present invention may be used to localize sites of inflammation, monitor inflammation over time, and/or screen for effective anti-inflammatory compounds. Molecules useful for targeting to sites of inflammation include the ELAN family of proteins, which bind to selections. An ELAN molecule can be incorporated as a targeting moiety on an entity of the present invention, and used to target inflammation sites.

Alternatively, an animal model for the study of putative anti-inflammatory substances can be made by making the animal transgenic for luciferase under the

00270631-070194

55

control of the E-selection promoter. Since E-selection is expressed at sites of inflammation, transgenic cells at sites of inflammation would express luciferase.

The system can be used to screen for anti-inflammatory substances. Inflammatory stimuli can be administered to control and experimental animals, and the effects of putative anti-inflammatory compounds evaluated by their effects on induced luminescence in treated animals relative to control animals.

10

D. Localization of Infection

As illustrated in experiments performed in support of the present invention and summarized above, LGCs may be effectively used to follow the course of infection of a subject by a pathogen. In experiments detailed herein, the LGCs are pathogenic cells (*Salmonella*) transformed to express luciferase. Such a system is ideally-suited to the study of infection, and the subsequent spread of infection, in animal models of human diseases. It provides the ability to monitor the progression of an infectious disease using sites of infection and disease progression rather than traditional systemic symptoms, such as fever, swelling, etc. in studies of pathogenesis.

Use of an external imaging method to monitor the efficacy of anti-infectives permits temporal and spatial evaluations in individual living animals, thereby reducing the number of animals needed for experiments pertaining to pathogenesis and/or the study anti-infective agents.

The following examples illustrate, but in no way are intended to limit the present invention.

0327064-0294

A. Cells

HEp-2 cells were obtained from the American Type Culture Collection (ATCC; 12301 Parklawn Dr., Rockville MD; Accession number CCL-23).

B. Static Cultures

15 Low oxygen (static) cultures were prepared by inoculating 3 ml of LB Broth containing 100 mg/ml of carbenicillin with 6 μ l of a bacterial suspension from a stationary phase culture, and growing the bacteria at 37°C overnight in a stationary 7 ml culture tube.

C. Mice

Balb/c (*Ity^{s/s}*) mice were obtained from the Department of Oncology, Stanford University. 129xBalb/c (*Ity^{r/s}*) mice were obtained from the Stanford Transgenic Animal Facility (Stanford, CA). All animals were housed under identical conditions of photo period, feeding regime and temperature in the Stanford University Research Animal Facility (Stanford, CA).

Anesthesia was performed by injecting the animals
30 intraperitoneally (i.p.) with 33 $\mu\text{g/kg}$ body weight
nembutal.

Euthanasia was performed by asphyxiation in CO₂ or cervical dislocation, following protocols recommended by the Stanford University Research Animal Facility.

Cervical dislocation was used in experiments in which results may have been affected by physiological changes due to asphyxia.

Mice infected with *lux*-transformed salmonella were given daily intramuscular (i.m.) injections of carbenicillin (125 mg per kg body weight) to maintain selective pressure on the luminescent salmonella for retention of the Amp^r plasmid containing the *lux* operon.

10 D. Imaging

Animals or objects to be imaged were immobilized in a light-tight box containing a door and a charge-coupled device (CCD) camera with a two stage microchannel intensifier head (model C2400-40, Hamamatsu). The camera was attached, via cables leading out of the box, to an "ARGUS 50" image processor (Hamamatsu).

The ICCD system described above is capable of detecting single photons once a threshold of 10-30 photons is achieved. The signal to noise ratio of the system ranged from 2:1 to $1 \times 10^4:1$, depending on signal intensity.

Grey-scale images were obtained by opening the light box door in dim room light and integrating for 8 - 64 frames. The gain for the gray scale images was set to optimize the image - typically at 3000 volts on a scale of 0 to 10,000 volts.

Bioluminescence data were obtained in absence of external illumination. Exposure settings were as follows: the black level was set automatically by the camera/image processor, the gain was adjusted automatically by the intensifier controller, and the f-stop was set at 2.8. A 60 mm "AF NIKKOR" macro lens was used (Nikon Inc., Melville, NY).

167070 FEB 02 2000

Bioluminescence images were generated by integrating photons for a selected period of time, typically 5 minutes. Data are presented at the lowest bit range setting of 0-3 bits per pixel for all animals. For images of other objects, i.e. 24 well plates, where the resolution of the bioluminescent signals was not possible at a bit range of 0-3, the range was increased to a setting that permitted localization of bioluminescent signals, typically 1-7. Objects were imaged for shorter periods of time when additional information could not be obtained by imaging for five minutes.

External imaging refers to non-invasive imaging of animals. Internal imaging refers to imaging after a partial dissection of the animals, typically a laparotomy. Internal imaging is performed in selected animals to confirm the sources of photon emission localized by external imaging.

The bioluminescence image data are presented as a pseudo-color luminescence image representing the intensity of the detected photons. Six levels of intensity are typically used, ranging from blue (low intensity) to red (higher intensity).

To generate the figures presented herein, greyscale and bioluminescence images were superimposed, using the image processor, to form a composite image providing a spatial frame of reference.

The composite image was displayed on an RGB CRT (red, green, blue; cathode ray tube) monitor, and the monitor was photographed to produce hardcopies. Hardcopies were also generated by saving the image processor image as a digital file, transferring the file to a computer, and printing it on a color printer attached to the computer. Alternatively, hardcopies

00220631.070404

60

5 TRANSFORMATION OF SALMONELLA WITH PCGLS1 LUX PLASMID

Salmonella strains SL1344, BJ66 and LB5000 were transformed with pCGLS1, a pUC18-based vector encoding the *lux* operon from *Xenorhabdus luminescens* (Frackman, et al., 1990).

10 A. pCGLS1 plasmid

A schematic of the pCGLS1 plasmid is shown in Figures 1A, 1B and 1C. The plasmid was constructed by cloning an ~11 kb region encoding the *lux* genes from

15 the soil bacterium *Xenorhabdus luminescens* (Fig. 1A; Frackman, et al., 1990) into the *Bam* HI site (Fig. 1B) of pUC18 (Fig. 1C; Clontech, Palo Alto, CA). The construction of the vector is described by Frackman, et al., (1990).

20 Restriction enzyme sites in Figure 1A are represented as follows: Bs, *Bst* EII; C, *Cla* I; E, *Eco* RI; H, *Hind* III; M, *Mlu* I; S, *Sca* I; X, *Xba* I; B/Sa, *Bam* HI and *Sau* 3A junction. A sequence included in the multiple cloning site (MCS) is provided in Figure 1B,

25 with the *Bam* HI site indicated in bold type.

A graphical representation of a pUC18 vector with no insert is shown in Figure 1C. Labeled elements include an ampicillin resistance gene (Ap), a *lac* Z gene (*lac* Z) and an *E. coli* origin of replication (*Ori*). The unmodified pUC18 vector is approximately

30 2.7 kb in size.

 B. Transformation of Salmonella

Electrocompetent cells from salmonella strains

35 SL1344, BJ66 and LB5000 were made using standard

methods (Sambrook, et al.) and stored at -80°C until just prior to use. Electroporation was performed as follows: $1\ \mu\text{l}$ of the plasmid ($0.2\ \mu\text{g}/\text{ml}$) was added to $40\ \mu\text{l}$ of ice-cold electrocompetent cells suspended in 10% glycerol. The suspension was mixed gently for one minute, placed in a 1 mm gap electroporation cuvette and electroporated using a Bio-Rad Gene-Pulser (Bio-Rad Laboratories, Hercules, CA). The settings were 2.5 kvolts, 400 ohms and $25\ \mu\text{farads}$.

Following a one hour agitated incubation in Luria Bertini (LB) broth at 37°C , the cells were plated on (LB) Agar containing $100\ \mu\text{g}/\text{ml}$ carbenicillin and allowed to grow overnight.

Colonies were assayed for luminescence by visual inspection in a dark room. Five transformants were identified as having high levels of luminescence. Three of these, one each from the SL1344, BJ66 and LB5000 strains, were selected for subsequent experiments. They were termed SL1344lux, BJ66lux and LB5000lux, respectively.

EXAMPLE 2

INVASIVE POTENTIAL OF NORMAL AND TRANSFORMED SALMONELLA

The invasive potential of six strains of salmonella (SL1344lux, LB5000lux, BJ66lux, SL1344, LB5000 and BJ66) was determined using two types of bacterial adherence and entry assays. Colony-forming units (CFU) assays were performed essentially as previously described (Finlay, et al.) with modifications (Lee, et al.). Bioluminescence assays were performed essentially like the CFU assays, except that the number of cells was quantitated using bioluminescence, as opposed to CFUs.

Briefly, HEP-2 cells and primary murine peritoneal macrophages were seeded into 24-well tissue culture

6704-1E902200

5 (macrophages) after cell seeding, bacteria from static cultures (see "Materials and Methods", above) were inoculated at 1×10^6 (multiplicity of infection (m.o.i.) of 10) or 1×10^7 (m.o.i. of 100, columns on right in Figs. 2B-E) organisms per well and centrifuged
10 onto the cell monolayer for 5 minutes at 1000 rpm (185 \times g) in a Beckman clinical centrifuge (Beckman Instruments, Columbia, MD). The medium was replaced with RPMI medium (Gibco/BRL) either with (entry assay) or without (adherence assay) gentamicin (100 mg/ml).
15 The co-cultures were incubated for a total of 3.5 hours at 35°C in 5% CO₂.

Gentamicin in the incubation medium kills bacteria that had not been internalized by the HEp-2 cells, including those adhering to the surfaces of the HEp-2 cells. Accordingly, the signal in adherence assays (without gentamicin) represent both adherent and internalized bacteria, whereas the signal in entry assays (with gentamicin) represent only internalized bacteria.

Adherence and entry were assayed by imaging luminescent bacterial cells at three timepoints - 1.5, 3.0 and 3.5 hours post inoculation. Prior to imaging at the first timepoint, the cell monolayer was washed three times with phosphate-buffered saline (PBS) to remove unattached bacteria and a fresh aliquot of RPMI medium was added. Luminescence was recorded using a 30 second exposure. Images at the second and third timepoints were obtained using a similar exposure, but without first washing the cells.

5

10

25

IN VITRO LUMINESCENCE OF TRANSFORMED SALMONELLA

The tubes were wrapped with clear plastic wrap and luminescence was determined by imaging for 30 seconds as described above. An exemplary image is shown in Figure 3. Four tubes are pictured. They contained (from top to bottom) 10^6 , 10^5 , 10^4 and 10^3 salmonella cells/ml (10^4 , 10^3 , 10^2 and 10 cells/tube). Luminescence could be detected in suspensions containing as few as 10^4 cells/ml (100 cells). The luminescence is confined, however, to air/liquid interfaces, suggesting that the luminescence reaction requires relatively high levels of oxygen. Since many of the cells are presumably in the fluid column and not at the air/fluid interfaces, the data suggest that the luminescence in the capillary tubes shown in Fig. 3 arises from considerably fewer than the total number of cells in each tube.

IN VITRO DETECTION OF LUMINESCENCE THROUGH ANIMAL TISSUE

64

contacted the sealed end of the tube and were exposed to air only at the upper end. The tubes were placed in a translucent plastic scintillation vial and surrounded by one of the following animal tissues: chicken breast muscle, chicken skin, lamb kidney or lamb renal medulla. All tissues were obtained from the meat department of a local supermarket (Safeway, Mountain View, CA).

A diagram of a vial containing a capillary tube surrounded by tissue is shown in Figure 4. The vial 1 is approximately 1.4 cm in diameter and includes a cap 2. The vial is coated with an opaque material (*i.e.* black tape) along its upper portion 3. Animal tissue 4 is placed in the vial such that it extends from the bottom of the vial to just above the bottom edge of the opaque coating 3. The micro test-tube 5 is sealed at the bottom by a plug 7 (*i.e.* a crytoseal plug), and is centered radially in the vial, with the plugged end of the tube touching or in close proximity to the bottom of the vial. The bacterial suspension 6 extends approximately 1 cm upward from the bottom of the tube.

Photons emitted from vials with and without tissue, and with and without bacteria, were counted using a liquid scintillation counter (model 1219 Rackbeta, LKB/Wallac, Gaithersburg, MD) with the fast coincidence discriminator disabled.

Controls without tissue were assayed by placing the bacterial suspension directly in the scintillation vial. All experiments were performed in triplicate.

In each experiment, the vials were counted two to three times, rotating the vial 90° between each count, to control for effects of possible tissue thickness inconsistency. No significant differences were detected.

The results are summarized in Table 2, below.

1467020 14904280

65

TABLE 2

TRANSMISSION OF PHOTONS THROUGH TISSUE				
Sample	Chicken skin	Chicken muscle	Lamb kidney	Lamb medulla
Vial alone	2.1×10^4	1.3×10^4	1.0×10^4	1.0×10^4
Tissue alone	N.D.	1.5×10^4	9.4×10^3	8.5×10^3
Tissue and LB5000lux*	2.7×10^5	2.3×10^5	1.6×10^4	1.5×10^5
LB5000lux* alone	2.0×10^6	1.7×10^6	4.8×10^6	4.8×10^6

Counts are averages of triplicate measurements, tissue path length was 1 cm. * - 1×10^7 cells.

The signal for 1×10^3 LB5000lux in kidney tissue was at or near background levels using the photomultiplier tubes (PMT) in the scintillation counter. The background in this type of detection is due to the dark current of the PMT and limits the studies to analysis of rather intense signals.

Bioluminescence from approximately 1×10^7 LB5000lux was detectable through 0.5 cm of avian muscle, skin ovine renal medulla and ovine kidney. These results indicate that bioluminescence from the labeled salmonella was detectable through animal tissues of variable opacity. Since oxygen was likely limited in the capillary tubes (as demonstrated in Fig. 3), it is likely that fewer numbers of bioluminescent salmonella could be detected through tissue than are indicated in this assay.

DETECTION OF ORALLY-ADMINISTERED LUX SALMONELLA IN BALB/C MICE

Representative images are shown in Figures 5A-F. At 24 hours post inoculation (p.i.), the bioluminescent signal localized to a single focus in all infected animals (Figs. 5A, 5C and 5E). Bioluminescence disappeared in all animals infected with the low virulence LB5000lux by 7 days p.i. (Fig. 5B). Animals infected with the virulent SL1344lux, on the other hand, showed virulent infection which often spread over much of the abdominal cavity (Fig. 5F). The spread of infection by BJ66lux was more variable, but the infection typically persisted and remained localized at the initial site (Fig. 5D).

25 DETECTION OF INFECTION FOLLOWING I.P. INOCULATION WITH A VIRULENT
AND A LOW VIRULENCE STRAIN OF SALMONELLA

At 32 hours post injection (p.i.), the mice were anesthetized and imaged as described above. The results are shown in Figure 6. Widespread infection is

evident in the two mice in the left part of the figure, infected with the virulent SL1344lux strain. In contrast, little, if any, luminescence is detected in the mice on the right, injected with the low virulence LB5000lux strain.

EXAMPLE 7

DETECTION OF SYSTEMIC INFECTION IN RESISTANT MICE FOLLOWING ORAL INOCULATION WITH SALMONELLA

Resistant 129xBalb/c (Ity^{+/+}) viable mice were infected by intragastric inoculation of 1×10^7 SL1344lux salmonella. The bacteria were introduced through an intra-gastric feeding tube while under anesthesia. The animals were imaged daily for 8 days post injection (d.p.i.).

Results are shown in Figures 7A and 7B. Mice, in triplicate, were infected and imaged daily for 8 days. Exemplary images for day 1 (Fig. 7A) and day 8 (Fig. 7B) are shown. These data indicate that mice resistant to systemic salmonella infection have a localized chronic infection in the cecum, but that the infection does not spread into the abdominal cavity.

EXAMPLE 8

POST-LAPAROTOMY IMAGING FOLLOWING ORAL INOCULATION WITH SALMONELLA

Laparotomy was performed following oral inoculation of salmonella to precisely localize the luminescent signal within the abdominal cavity; and to compare this localization with than obtained using non-invasive imaging. The animals were inoculated as described in Example 7. After a selected period of time, typically seven days, the mice were anesthetized and externally-imaged, as described above. An

447040 FEB 28 1980

5

10

15

20

25

30

69

weight; Sigma Chemical Co., St. Louis, MO). Following treatment of the experimental group, animals from both groups were imaged (as above) at several intervals over a period of 5.5 h post treatment.

5 Representative images are shown in Figures 10B-E. Figures 10B and 10D show composite images of representative animals from the control and treated groups, respectively, immediately before initiation of treatment of the experimental group. Figures 10C and
10 10E show composite images of the same animals 5.5 hours after initiation of treatment. The total number of photons detected over the abdominal area were determined, normalized to the value at $t=0$, and plotted in Figure 10A with respect to time post-treatment.

15 The data demonstrate that methods and compositions of the present invention can be used to evaluate the effects of drugs on the spread of infection in an animal model.

20 While the invention has been described with reference to specific methods and embodiments, it will be appreciated that various modifications and changes may be made without departing from the invention.

08270531-070494
101020-12302230

IT IS CLAIMED:

A
C1
1. A noninvasive method for detecting the localization of ^{an entity under study} ~~a biocompatible entity~~ ^{from within} in a mammalian subject, comprising

(a) administering to the subject a conjugate of the entity and a light-generating moiety ^{or transformed cell}

(b) after a period of time in which the conjugate can achieve localization in the subject, immobilizing the subject within the detection field of a photodetector device, ^{or transformed cell}

(c) maintaining the subject in an immobilized condition,

(d) during said maintaining, measuring photon emission from the light-generating moiety, localized in the subject, with the photodetector device until an image of photon emission can be constructed, and

(e) ~~constructing such an image.~~ ^{A1}

2. The method of claim 1, which further includes repeating steps (b) through (e) at selected intervals, wherein said repeating is effective to track the localization of the entity in the subject over time.

3. The method of claim 1, where said measuring is carried out with an intensified charge-coupled photodetector device.

4. The method of claim 1, for detecting the localization of tumor cells in a mammalian subject, where said administering includes administering a conjugate that contains a tumor cell targeting moiety.

5. The method of claim 1, for detecting the localization of inflammation in a mammalian subject,

1676204902290

71

5 4 6. The method of claim 1, for detecting the
localization of infection by a pathogen in a mammalian
subject, where said administering includes
administering a conjugate ^{or transformed cell} that contains an infection-
targeting moiety.

10 7. The method of claim 1, for detecting the
localization of thrombotic plaques in a mammalian
subject, where said administering includes
administering a conjugate that contains a thrombotic
15 plaque-targeting moiety.

8. The method of claim 1, where said administering includes administering a conjugate that is a particle containing a light-generating moiety.

9. The method of claim 1, for detecting the localization of infection by a pathogen in an animal model, where the ~~bio-compatible entity~~ is the pathogen.

25 10. The method of claim 9, where the pathogen is *Salmonella*.

8 11. The method of claim 1, where the light-
generating moiety is a light-generating protein.

12. The method of claim 11, where the protein is selected from the group consisting of luciferase, yellow fluorescent protein and ferredoxin IV.

13. The method of claim 11, where said administering includes administering a conjugate that is a fusion protein of an antibody fragment and a light-generating protein.

5

10 ~~14.~~ The method of claim ~~11~~, where the ~~biocompatible entity~~ is a transformed cell, and the light-generating moiety is a product of a heterologous gene expressed by the cell.

10

11 ~~15.~~ The method of claim ~~14~~, where expression of the heterologous gene is under the control of an activatable promoter.

15

12 ~~16.~~ A noninvasive method for detecting the level of a ~~biocompatible entity~~ in a mammalian subject over time, comprising

(a) administering to the subject a conjugate of the entity and a light-generating moiety,

20

(b) placing the subject within the detection field of a photodetector device,

(c) maintaining the subject in the detection field of the device,

25

(d) during said maintaining, measuring photon emission from the light-generating moiety, in the subject, with the photodetector device, and

30

(e) repeating steps (b) through (d) at selected intervals, wherein said repeating is effective to detect changes in the level of the entity in the subject over time.

17. A noninvasive method for detecting the integration of a transgene in a mammalian subject, comprising

(a) administering to the subject, a vector construct effective to integrate into mammalian cells and containing a transgene, a gene encoding a light-generating protein, and an activatable promoter, said
5 gene encoding a light-generating protein being under the control of said promoter,

(b) after a period of time in which the construct can achieve integration, activating said promoter,

(c) placing the subject within the detection field
10 of a photodetector device,

(d) maintaining the subject within the detection field of the photodetector device,

(e) during said maintaining, measuring the level of photon emission from expressed light-generating
15 protein, in the subject, with the photodetector device, and

(f) confirming integration of the transgene if the level of photon emission is significantly higher than background.

20

18. A noninvasive method for detecting the localization of a promoter-induction event in an animal, comprising

(a) triggering the event in a transgenic animal
25 having an inducible promoter responsive to such event and a heterologous gene encoding a light-generating protein under control thereof,

(b) placing the animal in the detection field of a photodetector device,

30 (c) maintaining the animal in an immobilized condition,

(d) during said maintaining, measuring photon emission from expressed light-generating protein, localized in the animal, with the photodetector device

44-38861-10000

until an image of photon emission can be constructed,
and

(e) constructing such an image.

- 5 19. Salmonella transformed with a gene expressing
a light-generating protein.

0327003 46302250

insert
B.

Patent Application Declaration and Power of Attorney

I HEREBY DECLARE THAT:

My residence, post office address, and citizenship are as stated next to my name in PART A on page 2 hereof.

I believe I am the original, first, and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Non-Invasive Localization of a Light-Emitting Conjugate in a Mammal

the specification of which:

- ☒ is attached hereto.
- ☐ was filed on _____ as Attorney Docket No. _____.
- ☐ was filed on _____ as Application Serial No. _____
and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed in PART B on page 2 hereof and have also identified in PART B on page 2 hereof any foreign application for patent or inventor's certificate having a filing date before that of the application of which priority is claimed.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed in PART C on page 2 hereof and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following as my attorney or agent with full power of substitution to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

Peter J. Dehlinger	Reg. No. 28,006
Gary R. Fabian	Reg. No. 33,875
Vincent M. Powers	Reg. No. 36,246
Charles K. Sholtz	Reg. No. P-38,615

whose mailing address for this application is: Dehlinger & Associates
P.O. Box 60850
Palo Alto, CA 94306

See Page 2 attached, signed, and made a part hereof.

Patent Application Declaration and Power of Attorney

PART A: Inventor Information and Signature

Full name of SOLE or FIRST inventor Christopher H. Contag
Citizenship U.S.A. Post Office Address 2017 California Street #5B
Mountain View, California 94040
Residence (if different) (same)
Inventor's Signature: _____ Date: _____

Full name of SECOND joint inventor, if any Pamela R. Contag
Citizenship U.S.A. Post Office Address 2017 California Street #5B
Mountain View, California 94040
Residence (if different) (same)
Second Inventor's Signature: _____ Date: _____

Full name of THIRD joint inventor, if any David A. Benaron
Citizenship U.S.A. Post Office Address 454 Birch Street
Redwood City, California 94062
Residence (if different) (same)
Third Inventor's Signature: _____ Date: _____

* * * * *

PART B: Prior Foreign Application(s)

Serial No.	Country	Day/Month/Year Filed	Priority Claimed	
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No

PART C: Claim for Benefit of Filing Date of Earlier U.S. Application(s)

Serial No.	Filing Date	Status:
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned

See Page 1 to which this is attached and from which this Page 2 continues.

over

A circular postmark from 'PAUL & TRADEMARK ONE'. The date '1994 JUL 1' is stamped in the center. The words 'NO MAIL ROOM' are curved along the bottom inner edge of the circle.